Skip to main content

Table 1 Clinical features of MOG 35-55 -immunized mice treated with mepazine or vehicle

From: Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis

Treatment Incidence Day of disease onseta Mean maximal clinical scorea
Vehicle 100% (8/8) 16.6 ± 0.9 3.8 ± 0.3
Mepazine 33% (3/10) 16.3 ± 1.3 2.1 ± 0.4b
  1. aResults are displayed as mean ± SEM.
  2. b P <0.01.